p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions
- PMID: 20225093
- DOI: 10.1007/s00428-010-0900-1
p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions
Abstract
Two N-terminal isoforms characterize the p63 protein: the transactivating isoform TAp63 and the amino-terminal truncated isoform DeltaNp63. Two further N-terminal isoforms lacking exon 4 (d4TAp63 and DeltaNp73L) have been reported. Purpose of the study was to investigate the molecular expression of N-terminal p63 isoforms in benign and malignant breast tissues. Eighteen randomly selected cases of invasive breast carcinoma (IBC) of luminal type, two cases of in situ duct carcinoma (DCIS/DIN), and 20 specimens of normal and benign breast tissues were studied. All cases were immunostained for p63. Reverse polymerase chain reaction and nested PCR were performed to evaluate p63 N-terminal expression patterns. These isoforms whenever present were validated by sequencing. All cases of normal breast, benign lesions, and the two cases of DCIS/DIN expressed DeltaNp63 and TAp63 isoforms only. The two variants lacking exon 4 (DeltaNp73L and d4TAp63) were not found. All invasive carcinomas expressed the DeltaNp63 and TAp63 isoforms as well as the two short isoforms lacking exon 4 which were found in 11 (d4TAp63) and four (DeltaNp73L) cases. The present cases of luminal-type IBC showed p63 isoforms together with short variants lacking exon 4. These isoforms were not observed in non-neoplastic breast tissue. Presence of p63 in invasive breast carcinomas of luminal type, as seen at molecular level, suggests caution to include p63 as a marker of basal-like carcinomas.
Similar articles
-
p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.Am J Surg Pathol. 2001 Aug;25(8):1054-60. doi: 10.1097/00000478-200108000-00010. Am J Surg Pathol. 2001. PMID: 11474290
-
Expression of c-kit in common benign and malignant breast lesions.Tumori. 2010 Nov-Dec;96(6):978-84. Tumori. 2010. PMID: 21388062
-
Differential expression of p63 isoforms in normal tissues and neoplastic cells.J Pathol. 2002 Dec;198(4):417-27. doi: 10.1002/path.1231. J Pathol. 2002. PMID: 12434410
-
Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.Histopathology. 2024 Apr;84(5):723-741. doi: 10.1111/his.15101. Epub 2023 Nov 27. Histopathology. 2024. PMID: 38012539 Review.
-
Possible Usage of p63 in Bioptic Diagnostics.Klin Onkol. 2018 Winter;31(Suppl 2):27-31. doi: 10.14735/amko20182S27. Klin Onkol. 2018. PMID: 31023021 Review. English.
Cited by
-
p63: a crucial player in epithelial stemness regulation.Oncogene. 2023 Nov;42(46):3371-3384. doi: 10.1038/s41388-023-02859-4. Epub 2023 Oct 17. Oncogene. 2023. PMID: 37848625 Free PMC article. Review.
-
p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility.Am J Clin Pathol. 2013 Dec;140(6):838-44. doi: 10.1309/AJCPE4PK6CTBNQJY. Am J Clin Pathol. 2013. PMID: 24225752 Free PMC article.
-
Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).Oncogene. 2013 May 23;32(21):2631-9. doi: 10.1038/onc.2012.286. Epub 2012 Jul 9. Oncogene. 2013. PMID: 22777354 Free PMC article.
-
p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27. Virchows Arch. 2018. PMID: 29484502
-
Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.J Cancer Res Clin Oncol. 2012 Aug;138(8):1271-8. doi: 10.1007/s00432-012-1200-8. Epub 2012 Mar 24. J Cancer Res Clin Oncol. 2012. PMID: 22441934
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous